Keywords: بوپراویر; CDV; Canine distemper virus; Ribavirin; Boceprevir; Antivirals;
مقالات ISI بوپراویر (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy
Keywords: بوپراویر; Hepatitis C; Relapse; Direct-acting antivirals; Neutralizing antibodies; Sustained virological response; E1E2 envelope; HCV; hepatitis C virus; DAA; direct-acting antiviral; SVR; sustained virological response; RBV; ribavirin; PEG-IFN; pegylated-interfero
Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan
Keywords: بوپراویر; Boceprevir; HBV; HCV; Taiwan;
A diastereoselective synthesis of boceprevir's gem-dimethyl bicyclic [3.1.0] proline intermediate from an insecticide ingredient cis-cypermethric acid
Keywords: بوپراویر; Boceprevir; Cypermethric acid; Dimethylcyclopropylproline; Hydroboration of vinyl chlorides; Oxidative esterification;
HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients
Keywords: بوپراویر; HIV/HCV-coinfection; HCV undetectable viral load; HCV sustained virologic response; SVR; Telaprevir; Boceprevir; HCV protease inhibitors; Low HCV viral load;
Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment
Keywords: بوپراویر; CNT; concentrative nucleoside transporter; GWAS; genome-wide association studies; Hb; haemoglobin; HCV; hepatitis C virus; ITPA; inosinetriphosphatase; SVR; sustained virological response; Anaemia; Hepatitis C; ITPA; SLC28; Polymorphism; Telaprevir; Bocep
Incidencia, manejo y coste de los efectos adversos hematológicos y dermatológicos durante las 12 primeras semanas de tratamiento con triple terapia para hepatitis C
Keywords: بوپراویر; Telaprevir; Boceprevir; Análisis de costes; Hepatitis C crónica; Efectos adversosTelaprevir; Boceprevir; Cost analysis; Chronic hepatitis C; Adverse effects
Research paperMolecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease
Keywords: بوپراویر; HCV; hepatitis C virus; MD; molecular dynamics; RMSD; root mean square deviation; RMSF; root mean square fluctuation; Rg; radius of gyration; VMD; visual molecular dynamics; HCV; Molecular dynamics; Simulations; Boceprevir; Resistance; Mutants;
Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C
Keywords: بوپراویر; Boceprevir; Hepatitis C; Resistance; Relapse
Período de lead-in y semana 8 como herramientas de predicción de la respuesta en el tratamiento con boceprevir: estudio retrospectivo de la práctica clínica real en España
Keywords: بوپراویر; VHC; Lead-in; Boceprevir; Peginterferón; Ribavirina; Respuesta virológica sostenidaHCV; lead-in; boceprevir; pegylated interferon; ribavirin; SVR
Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy
Keywords: بوپراویر; Boceprevir; breakthrough; HCV; resistance; triple therapy;
Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis
Keywords: بوپراویر; boceprevir; chronic hepatitis C; cost-effectiveness; genotype 1; pegylated interferon; ribavirin;
UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells
Keywords: بوپراویر; Tandem-mass; HCV; Intracellular; Boceprevir; Telaprevir; Chromatography;
Liver, pancreas and biliary tractDefer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents
Keywords: بوپراویر; Boceprevir; Chronic hepatitis C genotype 1; DAAs; Telaprevir; Therapy decision; Real-life data;
Liver, Pancreas and Biliary TractPersonalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C
Keywords: بوپراویر; Boceprevir; Cost-effectiveness; Peg-interferon;
Review articleTriple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF)
Keywords: بوپراویر; Boceprevir; Cirrhosis; Hepatitis C; Pegylated-interferon; Ribavirin; Telaprevir;
Research ArticleShould we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141)
Keywords: بوپراویر; Boceprevir; Chronic hepatitis C; Cost-effectiveness analysis; Direct-acting antivirals; Genotype 1; Interferon-free regimens; Model-based analysis; Telaprevir; Treatment initiation; G1; genotype 1; HCV; hepatitis C virus; TVR; telaprevir; BOC; boceprevir;
Research ArticleBoceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response
Keywords: بوپراویر; HCV; hepatitis C virus; BOC; boceprevir; PR; peginterferon with ribavirin; SVR; sustained virological response; TW; treatment week; NS3/4A; nonstructural proteins 3 and 4A; IU/ml; international units per milliliter; mITT; modified intent-to-treat; ITT; in
Research ArticleSafety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience
Keywords: بوپراویر; ALT; alanine aminotransferase; AFEF; French Association for the Study of the Liver; AUC; area under the curve; BID; twice daily (bis in die); BOC; boceprevir; cEVR; complete early virological response; CNI; calcineurin inhibitors; CYP; cytochrome P450; EP
My Treatment Approach to Chronic Hepatitis CÂ Virus
Keywords: بوپراویر; BOC; boceprevir; FDA; Food and Drug Administration; HCC; hepatocellular carcinoma; HCV; hepatitis C virus; HIV; human immunodeficiency virus; PEGINF; peginterferon; RBV; ribavirin; RVR; rapid virologic response; SMV; simeprevir; SOF; sofosbuvir; SVR; sust
Research ArticleSafety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: Meta-analysis of 5 trials
Keywords: بوپراویر; HCV; hepatitis C virus; BOC; boceprevir; P/R; peginterferon/ribavirin; SVR; sustained virologic response; MLR; multivariate logistic regression; AE; adverse event; TW; treatment week; SAE; serious adverse event; CI; confidence interval; Hepatitis C; Cirrh
Frontiers in Liver TransplantationDrug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting
Keywords: بوپراویر; ALT; Alanine aminotransferase; AST; Aspartate aminotransferase; AUC; Area under the curve; BOC; Boceprevir; BSEP; Bile salt export pump; Cmax; Maximum concentration; CNI; Calcineurin inhibitors; CYP; Cytochrome P450; DAA; Direct acting antivirals; DDI; Dr
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
Keywords: بوپراویر; AE; adverse event; ALT; alanine aminotransferase; BMI; body mass index; BOC; boceprevir; BT; viral breakthrough; CPGs; Clinical Practice Guidelines; CYP3A4; cytochrome p450 3A4; DAA; direct-acting antiviral; DVR; delayed virological response; EIA; enzyme
Kinetic Analyses Reveal Potent and Early Blockade of Hepatitis C Virus Assembly by NS5A Inhibitors
Keywords: بوپراویر; Antiviral Agent; Replication; Therapy; RNA-Dependent RNA Polymerase; BOC; boceprevir; CI; confidence interval; DAA; direct-acting antiviral; DCV; daclatasvir; EC50; 50% effective concentration; FFU; focus-forming unit; GLuc; Gaussia princeps luciferase; H
The Combination of MK-5172, Peginterferon, and Ribavirin Is Effective in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection Without Cirrhosis
Keywords: بوپراویر; Response-Guided Therapy; Sustained Virologic Response; Chronic HCV; Protease Inhibitor; ADME; absorption, distribution, metabolism, and excretion; ALT; alanine aminotransferase; AST; aspartate aminotransferase; BOC; boceprevir; cEVR; complete early virolo
CommentaryThe changing face of hepatitis C in the new era of direct-acting antivirals
Keywords: بوپراویر; Hepatitis C; Direct-acting antivirals; Human immunodeficiency virus; Telaprevir; Boceprevir; Antiviral therapy;
Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance
Keywords: بوپراویر; HCV; hepatitis C virus; UTR; untranslated regions; IFN; interferon; ISG; interferon stimulatory genes; IRES; internal ribosome entry site; IFNAR; IFN-α receptor; STAT; signal transducer and activator of transcription; TLR3; toll like receptor 3; DsRNA; d
Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies
Keywords: بوپراویر; HCV; Boceprevir; Variants; RAV; Resistance;
Research ArticleTriple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890
Keywords: بوپراویر; Chronic hepatitis C; Cirrhosis; Treatment; Boceprevir; Telaprevir; Safety; HCV; hepatitis C virus; ANRS; agence nationale de recherches sur le SIDA et les hépatites virales; AFEF; Association Française pour l'Etude du Foie; PegIFN; pegylated interfero
Research ArticleA multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C
Keywords: بوپراویر; CHC; chronic hepatitis C; HCC; hepatocellular carcinoma; SVR; sustained virological response; MSP; multidisciplinary support programme; pegIFN; pegylated interferon; DAA; direct-acting antivirals; TVR; telaprevir; BOC; boceprevir; RBV; ribavirin; HCV; hep
Research ArticleCost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C
Keywords: بوپراویر; CHC; chronic hepatitis C; G1; genotype 1; DT; dual therapy; PegIFN; pegylated interferon; RBV; ribavirin; PI; protease inhibitors; BOC; boceprevir; TVR; telaprevir; ICER; incremental cost-effectiveness ratio; NR; non-response; PAR; partial response; RR; r
Research ArticleEfficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis
Keywords: بوپراویر; BOC; boceprevir; PR; peginterferon-ribavirin; HCV-G1; hepatitis C virus, genotype-1; RGT; response guided therapy; SVR; sustained virologic response; HCC; hepatocellular carcinoma; NS3/4A; non-specific protein 3/4a.; HCV-G1 infection; Advanced fibrosis;
A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir
Keywords: بوپراویر; UPLC-MS/MS; Plasma; HCV; Telaprevir; Boceprevir;
Optimizing DAA management in daily practice
Keywords: بوپراویر; Adherence; Anaemia; Boceprevir; Drug–drug interaction; Educational nurse; Skin rash; Stopping rules; Telaprevir; Triple therapy
Avances en el tratamiento de la hepatitis C
Keywords: بوپراویر; Hepatitis C; Inhibidores de la proteasa; Boceprevir; Telaprevir; Interferón pegilado; RibavirinaHepatitis C; Protease inhibitors; Boceprevir; Telaprevir; Pegylated interferon; Ribavirine
Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response
Keywords: بوپراویر; Hepatitis C; HIV; Pegylated interferon; Ribavirin; Boceprevir; Telaprevir; IL28B; Rapid virological response
Directly acting antivirals for the treatment of chronic hepatitis C: Unresolved topics from registration trials
Keywords: بوپراویر; Boceprevir; Cirrhosis; Guidelines; HCV; IL28B; Lead-in; Telaprevir
Telaprevir Versus Boceprevir in Chronic Hepatitis C: A Meta-Analysis of Data From Phase II and III Trials
Keywords: بوپراویر; boceprevir; chronic hepatitis C; hepatitis C genotype 1; protease inhibitors; telaprevir
Emerging Therapeutic Targets for Hepatitis C Virus Infection
Keywords: بوپراویر; Hepatitis C; Direct Acting Antivirals; Interferon-free Therapy; Telaprevir; Boceprevir; DAA; direct acting antiviral; HCV; hepatitis C virus; IL; interleukin; NS; nonstructural; Peg-IFN; pegylated interferon; quad; quadruple; RBV; ribavirin; RGT; response
Boceprevir and Treatment of Chronic Hepatitis C
Keywords: بوپراویر; Boceprevir; Peginterferon; Ribavirin; Hepatitis C;
Boceprevir With Peginterferon Alfa-2a-Ribavirin Is Effective for Previously Treated Chronic Hepatitis C Genotype 1 Infection
Keywords: بوپراویر; Protease Inhibitor; Antiviral Therapy; Clinical Trial; Liver Disease; AE; adverse event; BOC; boceprevir; BOC/PEG2a/R; boceprevir plus peginterferon alfa-2a-ribavirin; CI; confidence interval; HCV; hepatitis C virus; OR; odds ratio; PEG2a; peginterferon
Validation of a fast method for quantitative analysis of elvitegravir, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other antiretroviral agents in human plasma samples with a new UPLC-MS/MS technology
Keywords: بوپراویر; ARV, antiretroviral drugs; IS, internal standard; Ct, plasma trough concentration; MRM, multiple reaction transition; TDM, therapeutic drug monitoring; UPLC-MS/MS, ultra-performance liquid chromatography-tandem mass spectrometryElvitegravir; Boceprevir; A
Prise en charge de l'hépatite C chronique : les dernières avancées thérapeutiques
Keywords: بوپراویر; Hépatite C chronique; Inhibiteur de protéase; Télaprévir; Bocéprévir; Antiviraux spécifiques; Chronic hepatitis C; Protease inhibitor; Telaprevir; Boceprevir; Direct-acting antivirals;
Management of the Transplant Recipient with Chronic Hepatitis C
Keywords: بوپراویر; Telaprevir; Boceprevir; Transplant; Hepatitis C virus;
Cost Effectiveness of Direct-Acting Antiviral Therapy for Treatment-Naive Patients With Chronic HCV Genotype 1 Infection in the Veterans Health Administration
Keywords: بوپراویر; Liver Disease; Cirrhosis; Prevention; Health Care Costs; boc; boceprevir; DAA; direct-acting antiviral; HCC; hepatocellular carcinoma; HCV; hepatitis C virus; ICER; incremental cost-effectiveness ratio; IL; interleukin; PR; pegylated interferon-alfa and r
Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients
Keywords: بوپراویر; Hepatitis C; Naive; Boceprevir; Telaprevir;
Virology of hepatitis C virus infection
Keywords: بوپراویر; HCV lifecycle; Real-time PCR; HCV RNA quantification; HCV genotype determination; Pegylated IFN-α; Ribavirin; Telaprevir; Boceprevir
Approach to the Treatment-naïve Patient with HCV Genotype 1 Infection
Keywords: بوپراویر; HCV genotype 1; Boceprevir; Telaprevir; Treatment-naïve patients;
Maximizing Opportunities and Avoiding Mistakes in Triple Therapy for Hepatitis C Virus
Keywords: بوپراویر; Hepatitis C; Boceprevir; Telaprevir; Safety; Triple Therapy; ADVANCE; a new direction in HCV Care: a study of treatment naïve hepatitis C patient with telaprevir; DAA; direct-acting antiviral; eRVR; extended rapid virologic response; HCV; hepatitis C vir
Meeting ReportHepatitis C infection, antiviral treatment and mental health: A European expert consensus statement
Keywords: بوپراویر; Hepatitis C; Interferon-alpha; Ribavirin; Telaprevir; Boceprevir; Depression; Fatigue; Cognitive disturbances; Side effects;